Originally known for managing blood sugar and weight, semaglutide is now emerging as a groundbreaking treatment for various addictions, from cocaine to alcohol and cannabis, by acting on the brain’s reward centers and offering a novel pharmacological approach where few exist.
For years, semaglutide—the active ingredient in popular medications like Ozempic and Wegovy—has been a cornerstone in the treatment of Type 2 diabetes and obesity. However, recent groundbreaking research suggests this powerful drug may have an even broader impact, offering a glimmer of hope in the persistent battle against substance use disorders. Scientists are uncovering how semaglutide could become a critical tool in reducing cravings and preventing relapse for some of the world’s most challenging addictions, including cocaine, alcohol, and cannabis.
The Science Behind the Surprising Discovery
The key to semaglutide‘s unexpected utility lies in its interaction with glucagon-like peptide-1 receptors (GLP-1Rs). While these receptors are well-known for their role in the pancreas, regulating blood sugar, they are also present in the brain’s reward centers. This dual location is crucial, as GLP-1Rs modulate both appetite and impulse control. Researchers hypothesized that if semaglutide could effectively curb hunger cravings, it might similarly diminish the intense cravings associated with drug seeking.
Further investigation revealed a deeper mechanism: semaglutide appears to dim the brain’s reward signal. Cocaine, for instance, typically triggers a flood of dopamine, the neurotransmitter associated with pleasure and reward, in the nucleus accumbens. However, in studies involving semaglutide-pretreated animals, this dopamine surge was significantly subdued. The drug didn’t alter baseline dopamine levels but specifically lowered the heightened rush induced by cocaine, making the substance less stimulating on a chemical level and reducing the compulsive drive to take it.
Tackling Cocaine Addiction: A New Hope
Cocaine use disorder has long been one of the most intractable addictions, with no FDA-approved medications and alarmingly high relapse rates. The intense cravings and compulsive drug-seeking behavior often pull individuals back into substance use, even after extended periods of sobriety. This pressing need for effective treatments has driven researchers to explore unconventional paths.
Scientists at the University of Gothenburg and the University of Pennsylvania conducted pioneering studies using male Sprague-Dawley rats, which were trained to self-administer cocaine. The results, published in European Neuropsychopharmacology, were striking. At moderate and high doses, semaglutide reduced cocaine intake by as much as 26 percent and cut the motivation to obtain the drug in half. Even more profoundly, the drug reduced relapse-like behavior by over 60 percent, significantly blunting the intense cravings that typically follow a “reminder” dose of cocaine.
Lead researcher Cajsa Aranäs from the Sahlgrenska Academy in Gothenburg noted that an already established drug could influence important behaviors behind cocaine addiction. Her co-worker, Professor Elisabet Jerlhag, highlighted the urgent need for treatments, stating that “there are no medications currently available, and the relapse risk is very high.” These findings, if confirmed in human clinical trials, could provide cocaine abusers with their first legitimate pharmacological treatment for maintaining sobriety, as reported in European Neuropsychopharmacology.
Addressing Alcohol Use Disorder (AUD)
The potential of GLP-1 agonists like semaglutide extends beyond cocaine. Preclinical research in rodents and monkeys, much of it conducted by Elisabet Jerlhag Holm and her team at the University of Gothenburg since 2012, has shown promising effects in reducing the consumption of not just food, but also alcohol. These studies, published in Frontiers in Pharmacology and eBiomedicine, demonstrated that even low doses of semaglutide could reduce alcohol intake in rats.
Crucially, the first human data on semaglutide for Alcohol Use Disorder (AUD) has emerged. A report published in the Journal of Clinical Psychiatry by Kyle Simmons and Jesse Richards detailed six patients who, while receiving semaglutide for weight loss, also showed significant improvement in their alcohol-related symptoms. All six patients had initial AUDIT scores indicating positive AUD, which then fell to levels consistent with “low-risk” drinking after starting semaglutide. This strong response, even at low doses, has fueled interest in larger studies.
Currently, a randomized placebo-controlled trial known as the STAR (Semaglutide Therapy for Alcohol Reduction) study is underway, led by Kyle Simmons, with a sister study also being conducted in Baltimore by the National Institute on Drug Abuse (NIDA). With only three FDA-approved pharmacotherapies for AUD and limited patient uptake, the prospect of a new, well-tolerated treatment with a different mechanism is a significant development, as discussed in Medscape Medical News.
Insights into Cannabis Use Disorder (CUD)
The reach of semaglutide‘s unexpected benefits also seems to include Cannabis Use Disorder (CUD). Researchers, including Nora Volkow, the director of NIDA, investigated this in a real-world human study using electronic health records. The study examined large populations of patients with obesity and Type 2 diabetes, comparing those who received semaglutide to those who did not.
The findings, published in Molecular Psychiatry, were compelling. Obese patients prescribed semaglutide had a 44% lower risk for a new CUD diagnosis and were 38% less likely to have a recurrent CUD diagnosis during the study period. Similar results were seen in the Type 2 diabetes cohort, with a 60% lower incidence of new CUD diagnoses and a 34% lower rate of recurrent CUD. These “incidental” findings, where patients weren’t specifically looking to reduce cannabis use, suggest a genuine effect beyond placebo.
Given the current absence of any substantially effective medication for assisting CUD treatment, these results are incredibly significant. While further preclinical work is needed to fully understand the mechanism, and randomized clinical trials are essential for clinical use, this represents a crucial step forward for patients and therapists alike, as detailed in Molecular Psychiatry.
Broader Implications for Addiction Treatment
The potential of semaglutide to impact multiple substance use disorders marks a pivotal moment in addiction medicine. The fact that this drug is already FDA-approved for diabetes and obesity means its safety profile is well-established, potentially fast-tracking the clinical trial process for its new applications in addiction. This is a massive advantage compared to developing entirely new compounds.
More fundamentally, this research opens up a novel domain for understanding and treating addiction. By demonstrating how metabolic pathways can influence craving and self-control, scientists are beginning to connect appetite biology with drug response in ways previously unexplored. This holistic approach, moving beyond brain chemistry alone, could lead to a new generation of addiction medicines capable of reducing the euphoria of cocaine and possibly other drugs of abuse, offering a fresh perspective on a long-standing challenge.
The Road Ahead: Clinical Trials and Community Impact
While the preclinical and early human data are incredibly promising, the scientific community eagerly awaits the results of larger, randomized controlled clinical trials. These trials will be critical to definitively establish semaglutide‘s safety and efficacy as a treatment for addiction in humans. If confirmed, this drug could truly transform the landscape of addiction treatment, providing a much-needed pharmacological aid to complement existing therapies.
For individuals struggling with substance use, and for the dedicated professionals working in addiction recovery, semaglutide represents a beacon of hope. Its potential to offer the first effective pharmacological assistance for maintaining sobriety for various addictions could empower countless individuals on their journey to recovery, ushering in a new era of evidence-based, compassionate care.
